See more : Brookfield Property Partners L.P. (BPYPN) Income Statement Analysis – Financial Results
Complete financial analysis of THC Therapeutics, Inc. (THCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of THC Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Murata Manufacturing Co., Ltd. (6981.T) Income Statement Analysis – Financial Results
- Payfare Inc. (PYFRF) Income Statement Analysis – Financial Results
- UT Group Co., Ltd. (2146.T) Income Statement Analysis – Financial Results
- Bharat Petroleum Corporation Limited (BPCL.BO) Income Statement Analysis – Financial Results
- Fuji Seal International, Inc. (7864.T) Income Statement Analysis – Financial Results
THC Therapeutics, Inc. (THCT)
About THC Therapeutics, Inc.
THC Therapeutics, Inc. operates in the wellness industry. It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. The company was formerly known as Millennium Blockchain, Inc. and changed its name to THC Therapeutics, Inc. in September 2018. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas, Nevada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00 |
| Cost of Revenue | 1.39K | 12.33K | 16.37K | 20.11K | 25.56K | 25.43K | 10.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.39K | -12.33K | -16.37K | -20.11K | -25.56K | -25.43K | -10.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 306.16K | 1.75M | 939.98K | 1.30M | 24.23M | 744.48K | 276.16K | 92.85K | 273.28K | 552.83K | 364.70K | 240.35K | 23.57K | 115.41K | 0.00 | 8.41K | 0.00 |
| Selling & Marketing | 187.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 493.91K | 1.75M | 939.98K | 1.30M | 24.23M | 744.48K | 276.16K | 92.85K | 273.28K | 552.83K | 364.70K | 240.35K | 23.57K | 115.41K | 68.79K | 8.41K | 353.00 |
| Other Expenses | 0.00 | 1.43M | 473.15K | 20.11K | 25.56K | 25.43K | 152.86K | 0.00 | 0.00 | 0.00 | -760.00K | 0.00 | 0.00 | -1.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 493.91K | 1.75M | 939.98K | 1.32M | 24.26M | 769.92K | 429.02K | 92.85K | 273.28K | 552.83K | 364.70K | 240.35K | 23.57K | 124.41K | 68.79K | 8.41K | 353.00 |
| Cost & Expenses | 493.91K | 1.75M | 939.98K | 1.32M | 24.26M | 769.92K | 429.02K | 92.85K | 273.28K | 552.83K | 364.70K | 240.35K | 23.57K | 124.41K | 68.79K | 8.41K | 353.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 79.58K | 100.40K | 551.75K | 487.70K | 303.59K | 101.69K | 164.27K | 11.28K | 11.02K | 46.31K | 5.49K | 1.20K | 1.20K | 201.00 | 83.00 | 1.59K | 0.00 |
| Depreciation & Amortization | 1.39K | 12.33K | 16.37K | 20.11K | 25.56K | 25.43K | 10.49K | 103.53K | 0.00 | 23.09K | -762.95K | 2.00 | 2.00 | 84.61K | -1.13K | -1.59K | 0.00 |
| EBITDA | -492.52K | -1.73M | -923.61K | -1.37M | -24.23M | -6.01M | -210.29K | -263.31K | -273.28K | -554.91K | -1.13M | -240.35K | -23.57K | -37.66K | -68.79K | -15.63K | -153.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -76.50% |
| Operating Income | -493.91K | -1.75M | -939.98K | -1.32M | -26.69M | -5.99M | -429.02K | -92.85K | -273.28K | -552.83K | -364.70K | -240.35K | -23.57K | -124.41K | -68.79K | -8.41K | -153.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -76.50% |
| Total Other Income/Expenses | 106.88K | 227.10K | -945.47K | -540.99K | 3.38M | -147.48K | 43.31K | -202.15K | -11.02K | -23.22K | -768.43K | -1.20K | -1.20K | 86.55K | -83.00 | -7.30K | 153.00 |
| Income Before Tax | -387.04K | -1.52M | -1.89M | -1.93M | -23.31M | -6.14M | -15.60M | -92.00K | -284.30K | -576.05K | -1.13M | -241.55K | -24.77K | -37.86K | -68.87K | -8.49K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -227.10K | 551.75K | 487.70K | 303.59K | 147.48K | 15.17M | -12.13K | 0.00 | -23.09K | 762.95K | -2.00 | -2.00 | -84.61K | 1.13K | 1.59K | 153.00 |
| Net Income | -387.04K | -1.29M | -2.44M | -2.41M | -23.61M | -6.14M | -15.60M | -92.00K | -284.30K | -576.05K | -1.13M | -241.55K | -24.77K | -37.86K | -68.87K | -8.49K | -153.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -76.50% |
| EPS | -0.01 | -0.04 | -0.10 | -0.15 | -1.77 | -0.51 | -2.37 | -0.16 | -0.52 | -1.06 | -2.46 | -0.93 | -0.01 | -0.03 | -0.12 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.04 | -0.10 | -0.15 | -1.77 | -0.51 | -2.37 | -0.16 | -0.52 | -1.06 | -2.46 | -0.93 | -0.01 | -0.03 | -0.12 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 32.81M | 33.24M | 23.66M | 16.55M | 13.38M | 12.05M | 6.59M | 569.79K | 543.12K | 541.54K | 461.38K | 258.47K | 1.95M | 1.11M | 588.89K | 588.89K | 589.36K |
| Weighted Avg Shares Out (Dil) | 32.81M | 33.24M | 23.66M | 16.55M | 13.38M | 12.05M | 6.59M | 569.79K | 543.12K | 541.54K | 461.38K | 258.47K | 1.95M | 1.11M | 588.89K | 588.89K | 589.36K |
THC Therapeutics Secures $50M From Shefford Capital Partners To Support Cannabis Acquisitions
Cannabis-focused technology company THC Therapeutics, Inc. (OTCMKTS: THCT) revealed Friday that it has secured up to $50 million in funding from Shefford Capital Partners for acquisitions in the cannabis, alternative therapies and modern health space. Shefford Capital Partners is a...
THC Therapeutics Has Completed the dHydronator(R) Consumer Model Design
THCT has leveraged the extensive market research commissioned through Keyhole Research to redesign the dHydronator® for the consumer market. This new design is in the rapid prototyping phasein preparation for mass manufacturing.
THC Therapeutics Has Completed the dHydronator® Consumer Model Design with photos
THCT has leveraged the extensive market research commissioned through Keyhole Research to redesign the dHydronator® (Patented Cannabis sanitizing dryer) for the consumer market. This new design is in the rapid prototyping phase in preparation for mass manufacturing.
THC Therapeutics Engage Milestone Management Services for Investor Relations
LAS VEGAS, April 08, 2021 (GLOBE NEWSWIRE) -- THC Therapeutics, Inc. (THCT), a forward-thinking, publicly-traded health and technology company, whose mission statement is "Better Health through the Science of Nature," announced it has finalized an agreement to engage Milestone Management...
THC Therapeutics Has Begun the Process of Acquiring A Significant Amount of Physical Silver Bullion
The company has leveraged the Founder & Chairman's network to acquire physical silver at a very low premium above spot price and we intend to continue doing so.
THC Therapeutics Has Joined the Las Vegas Medical Marijuana Association.
The company will utilize the connections of the LVMMA to raise capital, and seek mergers & acquisitions.
Future Business Plans of THC Therapeutics on Increasing Shareholder Value Via a Reg A+
THCT is in the process of raising up to 75 Million with a Reg A+ to implement our business strategy.
THC Therapeutics, Inc. Independently Tested, Patented Sanitizing Cannabis Dryer More Relevant Than Ever
The dHydronator's SanitiZen® technology has been proven to reduce the microbial load level of cannabis from failing laboratory testing and brings the contaminants down to passing levels.
Source: https://incomestatements.info
Category: Stock Reports